Disclaimer
This Guideline a empts to define principles of prac ce that should produce high-quality
pa ent care. It is applicable to specialists, primary care providers and ancillary healthcare
providers. This Guideline should not be considered exclusive of other methods of care
reasonably directed at obtaining the same results. The ul mate judgment concerning the
propriety of any course of conduct must be made by the clinician a er considera on of each
individual pa ent situa on.
Neither IGC, SITC, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Abbrevia ons
CNS, central nervous system; DFS, disease-free survival; ECOG, Eastern Coopera ve
Oncology Group; HD, high dose; HQ, hydroxychloroquine; IFN, interferon; IL, interleukin;
mRCC, metasta c RCC; OS, overall survival; PD, programmed death; PFS, progression-free
survival; PS, performance status; RCC, renal cell carcinoma; RFS, recurrence-free survival;
RT, radia on therapy; SD, stable disease; SBRT, stereotac c body radia on therapy; S/P,
status post; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor
Source
Rini BI, McDermo DF, Hammers H, Bro W, Bukowski RM, Faba B, Faba J, Figlin RA,
Hutson T, Jonasch E, Joseph RW, Leibovich BC, Olencki T, Pantuck AJ, Quinn DI, Seery V,
Voss MH, Wood CG, Wood LS, Atkins MB. Society for Immunotherapy of Cancer consensus
statement on immunotherapy for the treatment of renal cell carcinoma. J Immunother
Cancer. 2016 Nov 15;4:81. jitc.biomedcentral.com.
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2017 All rights reserved
SITCRCC17053e
Defini on of Evidence Grades
Level Defini on
A Strong suppor ng evidence-based data from prospec ve, randomized,
controlled trials, meta-analyses, long-term follow-up of prospec ve,
uncontrolled trials (HD IL-2 only)
B Moderate suppor ng data from uncontrolled, prospec ve clinical trials
C Weak suppor ng data from retrospec ve reviews and case reports
Percentages Propor on of Task Force members favoring recommenda on
